1. Describe current standard‑of‑care management for limited‑stage and extensive‑stage small‑cell lung cancer (SCLC), including the role of chemo‑immunotherapy and consolidation strategies.
2. Interpreting key clinical trial data (ADRIATIC, IMpower133, CASPIAN, IMforte, DeLLphi‑304) and apply results to real‑world treatment decisions.
3. Explaining the role of immunotherapy and bispecific T‑cell engagers (BiTEs), particularly DLL3‑targeted therapy with tarlatamab, in relapsed SCLC.
4. Recognizing and managing unique toxicities associated with BiTE therapy, including cytokine release syndrome (CRS), ICANS, and dysgeusia.
5. Discussing emerging therapies and future directions in SCLC, including antibody–drug conjugates (e.g., ifinatamab deruxtecan) and strategies to improve durability of response and access to care.